Black Diamond Therapeutics, Inc. announced the appointment of Christopher D. Roberts, Ph.D., as Chief Scientific Officer. In this role, Chris will oversee all Black Diamond's research and early development. The company also announced the addition of Matt Lucas, Ph.D., as Vice President of Chemistry, based in Cambridge, MA, and Tai-An Lin, Ph.D., as VP and Head of Biology, based in Black Diamond's labs in New York, NY. Chris Roberts brings more than two decades of experience leading discovery and development functions and clinical development projects for multiple therapies in oncology and immunology. He joins Black Diamond from SR One, the corporate venture capital arm of GlaxoSmithKline (GSK), where he was an Entrepreneur in Residence. Matt Lucas, Black Diamond's VP of Chemistry, has more than 17 years of drug discovery experience at small and mid-sized biotech companies and large pharmaceutical organizations. Prior to joining Black Diamond as VP of Chemistry, he served as Senior Director of Chemistry at Yumanity Therapeutics. Before that, Matt served as Director of Chemistry at Cubist Pharmaceuticals and as Head of Exploratory Inflammation Chemistry at Roche.